Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A light at the end of the tunnel - from mutation identification to a potential treatment for Alzheimer's disease.

Upsala journal of medical sciences - 1 Jan 2023

Lannfelt Lars

Abstract excerpt

Recent advances have driven the development of immunotherapies that act by either promoting or suppressing a patient's immune system to treat inflammation, autoimmune disease, cardiovascular disease, infectious diseases, and several cancers. In addition, research conducted over the past 25 years has identified therapeutic targets and indicated that immunotherapy could be used to treat Alzheimer's disease (AD)....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alzheimer Disease
Share to Amyloid beta-Peptides
Share to Amyloid beta-Protein Precursor

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Mice, Transgenic

Share to Mutation

Source

Open in PubMed Open full text

Identifiers

PMID: 38084203
DOI: 10.48101/ujms.v128.10316
PMCID: PMC10710852

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A light at the end of the tunnel - from mutation identification to a potential treatment for Alzheimer's disease.PMID 38084203Read ↗

Biologics as Therapeutical Agents Under Perspective Clinical Studies for Alzheimer’s DiseaseSemantic proximity Read ↗

Genomics of Alzheimer Disease: A Review.Semantic proximity Read ↗

FDA-Approved Passive Immunization Treatments Against Aβ in Alzheimer’s Disease: Where Are We Now?Semantic proximity Read ↗

Defining molecular targets to prevent Alzheimer disease.Semantic proximity Read ↗

Molecular Therapeutics in Development to Treat Alzheimer’s DiseaseSemantic proximity Read ↗

Unraveling the Gordian knot: genetics and the troubled road to effective therapeutics for Alzheimer's disease.Semantic proximity Read ↗

The Alzheimer’s therapeutic Lecanemab induces an amyloid-clearing program in microgliaSemantic proximity Read ↗

Aggregation-Dependent Epitope Sequence and Modification Fingerprints of Anti-Aβ AntibodiesSemantic proximity Read ↗

Developing theragnostics for Alzheimer's disease: Insights from cancer treatmentSemantic proximity Read ↗

Amyloid fibril polymorphism: a challenge for molecular imaging and therapySemantic proximity Read ↗

Alzheimer's Disease; Mechanism, Mutations, and Applications of Nano-Medicine.Semantic proximity Read ↗

Translational research on the way to effective therapy for Alzheimer disease.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.